# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
eMagin Corporation (NYSE:EMAN) ("eMagin" or the "Company"), a U.S.-based leader in the development, design, an...
eMagin shareholders as of the close of business on July 20, 2023, are eligible to vote on the pending transaction and are encou...
HC Wainwright & Co. analyst Kevin Dede downgrades eMagin (AMEX:EMAN) from Buy to Neutral.
eMagin (AMEX:EMAN) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.03) by 333...
Companies Reporting Before The Bell • IDEX Biometrics (NASDAQ:IDBA) is estimated to report quarterly loss at $0.39 per share o...
HC Wainwright & Co. analyst Kevin Dede reiterates eMagin (AMEX:EMAN) with a Buy and maintains $3 price target.